Skip to main content

Main menu

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2021
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN

User menu

Search

  • Advanced search
CMAJ
  • CMAJ JOURNALS
    • CMAJ Open
    • CJS
    • JAMC
    • JPN
CMAJ

Advanced Search

  • Home
  • COVID-19
    • Articles & podcasts
    • Blog posts
    • Collection
    • News
  • Content
    • Current issue
    • Past issues
    • Early releases
    • Collections
    • Sections
    • Blog
    • Infographics & illustrations
    • Podcasts
  • Authors
    • Overview for authors
    • Submission guidelines
    • Submit a manuscript
    • Forms
    • Editorial process
    • Editorial policies
    • Peer review process
    • Publication fees
    • Reprint requests
  • CMA Members
    • Overview for members
    • Earn CPD Credits
    • Print copies of CMAJ
    • Career Ad Discount
  • Subscribers
    • General information
    • View prices
  • Alerts
    • Email alerts
    • RSS
  • JAMC
    • À propos
    • Numéro en cours
    • Archives
    • Sections
    • Abonnement
    • Alertes
    • Trousse média 2021
  • Visit CMAJ on Facebook
  • Follow CMAJ on Twitter
  • Follow CMAJ on Pinterest
  • Follow CMAJ on Youtube
  • Follow CMAJ on Instagram
Letters

Anaphylaxis treatment: the details

Axel Ellrodt
CMAJ November 25, 2003 169 (11) 1148;
Axel Ellrodt
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Metrics
  • Responses
  • PDF
Loading

Having read the review article by Anne Ellis and James Day,1 I have several questions about drug therapy for anaphylaxis.

Ellis and Day1 report that patients seen in their unit are usually discharged with a 4-day prescription for prednisone and diphenhydramine, a relatively common approach. However, given that many patients must drive or go to work, I wonder why the authors do not advocate one of the newer nonsedative antihistamines. Similarly, would it be appropriate to recommend the addition of ranitidine for 48 hours, on the basis of the experimental evidence presented by Ellis and Day1 and given the risk of a biphasic reaction? Since the second-phase reaction may be more severe than the primary reaction,1 this approach might be safer, although it is as yet unproved. I also wondered what dosage of prednisone is recommended for postdischarge therapy and whether the dose should be tapered.

Ellis and Day1 mention the cross-reactivity between cephalosporin and penicillin, but there have been conflicting recommendations as to whether this applies to the third-generation cephalosporins. Kelkar and Li2 recommended against prescribing third-generation cephalosporins to patients allergic to penicillin, but their review was based on extrapolation and inference. Anne and Reisman3 concluded that it is safe to administer cephalosporin antibiotics, especially third-generation drugs, to penicillin-allergic patients. Pumphrey and Davis4 reported 6 anaphylactic deaths after a first cephalosporin dose, which occurred over a 5-year period in the United Kingdom. Three of these patients had a penicillin allergy, but the generation of the cephalosporins in these cases was not indicated. In my own experience, many physicians in France are not reluctant to use third-generation cephalosporins, when indicated, for penicillin-allergic patients (in the hospital environment).

Finally, prescribing epinephrine as volumes of a 1:1000 solution is a potentially dangerous dosing system. Administering epinephrine measured in micrograms (or milligrams), as pumped from clearly labelled ampoules, might avoid inadvertent ventricular tachycardia.

Axel Ellrodt Emergency Department American Hospital of Paris Paris, France

Footnotes

  • Competing interests: None declared.

References

  1. 1.↵
    Ellis AK, Day JH. Diagnosis and management of anaphylaxis. CMAJ 2003;169(4):307-12.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    Kelkar PS, Li JT. Cephalosporin allergy. N Engl J Med 2001;345(11):804-9.
    OpenUrlCrossRefPubMed
  3. 3.↵
    Anne S, Reisman RE. Risk of administering cephalosporin antibiotics to patients with histories of penicillin allergy. Ann Allergy Asthma Immunol 1995;74:167-70.
    OpenUrlPubMed
  4. 4.↵
    Pumphrey RS, Davis S. Under-reporting of antibiotic anaphylaxis may put patients at risk [letter]. Lancet 1999;353:1157-8.
    OpenUrlPubMed
PreviousNext
Back to top

In this issue

Canadian Medical Association Journal: 169 (11)
CMAJ
Vol. 169, Issue 11
25 Nov 2003
  • Table of Contents
  • Index by author

Article tools

Respond to this article
Print
Download PDF
Article Alerts
To sign up for email alerts or to access your current email alerts, enter your email address below:
Email Article

Thank you for your interest in spreading the word on CMAJ.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Anaphylaxis treatment: the details
(Your Name) has sent you a message from CMAJ
(Your Name) thought you would like to see the CMAJ web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Anaphylaxis treatment: the details
Axel Ellrodt
CMAJ Nov 2003, 169 (11) 1148;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
‍ Request Permissions
Share
Anaphylaxis treatment: the details
Axel Ellrodt
CMAJ Nov 2003, 169 (11) 1148;
Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Footnotes
    • References
  • Responses
  • Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Eliminating racism in research
  • Transitioning to outpatient arthroplasty during COVID-19: time to pivot
  • Systemic absorption of intranasal corticosteroids may occur and can potentially affect the hypothalamic–pituitary–adrenal axis
Show more Letters

Similar Articles

Collections

  • Topics
    • Allergy

Content

  • Current issue
  • Past issues
  • Collections
  • Sections
  • Blog
  • Podcasts
  • Alerts
  • RSS
  • Early releases

Information for

  • Advertisers
  • Authors
  • Reviewers
  • CMA Members
  • Media
  • Reprint requests
  • Subscribers

About

  • General Information
  • Journal staff
  • Editorial Board
  • Governance Council
  • Journal Oversight
  • Careers
  • Contact
  • Copyright and Permissions

Copyright 2021, Joule Inc. or its licensors. All rights reserved. ISSN 1488-2329 (e) 0820-3946 (p)

All editorial matter in CMAJ represents the opinions of the authors and not necessarily those of the Canadian Medical Association or its subsidiaries.

To receive any of the resources on this site in an accessible format, please contact us at cmajgroup@cmaj.ca.

Powered by HighWire